Javier Martin Broto, MD, PhD, Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain, explains how there are many subtypes of sarcoma, which respond differently to select treatments. In ultra-rare sarcomas, unique approaches have been developed over the last decade. Immunotherapy has been shown to be vital, with anti-PD1 therapy in alveolar soft part sarcoma (ASPS). CSF1 inhibitors, such as pexidartinib, are an example of tyrosine-kinase inhibitors (TKIs) for rare sarcomas. In common sarcoma types, new combinations and targets are still being investigated. Recently, cabozantinib has be trialed in different sarcoma types. It is important to remember that different sarcoma subtypes will show different levels of response to novel TKIs. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
